TMBIM6

Across TCGA pan-cancer cohorts, TMBIM6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMBIM6 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMBIM6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMBIM6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where TMBIM6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.747	1.000	.002	43	view →
PDAC	OS	Quartile	III,IV	0.416	0.971	.005	12	view →
CCRCC	DFS	Median	III,IV	0.541	0.817	.030	11	view →
OV	DFS	Tertile	All	0.542	1.000	.020	8	view →
HNSC	DFS	Quartile	II,III,IV	0.859	0.583	.023	6	view →
LSCC	DFS	Tertile	All	1.000	0.848	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMBIM6–LUAD (OS)

Open the LUAD breakdown →